Andreas Pfützner

Articles in Scholarly Journals [Incomplete List]

  1. C-Peptide and Its C-Terminal Fragments Improve Erythrocyte Deformability in Type 1 Diabetes Patients
    Experimental Diabetes Research, vol. 2008, Article ID 730594, 6 pages, 2008
  2. Influence of C-Peptide on Glucose Utilisation
    Experimental Diabetes Research, vol. 2008, Article ID 769483, 3 pages, 2008
  3. Fixed-dose combination of pioglitazone and glimepiride in the treatment of Type 2 diabetes mellitus
    Expert Review of Endocrinology & Metabolism, vol. 2, no. 3, pp. 303–312, 2007
  4. Rosiglitazone and glimeperide: review of clinical results supporting a fixed dose combination
    Vascular Health and Risk Management, vol. 3, no. 2, pp. 211–220, 2007
  5. Pioglitazone: update on an oral antidiabetic drug with antiatherosclerotic effects
    Expert Opinion on Pharmacotherapy, vol. 8, no. 12, pp. 1985–1998, 2007
  6. A Diabetes Outcome and Progression Trial – Die ADOPT Studie
    Der Diabetologe, vol. 3, no. 4, pp. 261–269, 2007
  7. Anti-Inflammatory Effects of Pioglitazone and/or Simvastatin in High Cardiovascular Risk Patients With Elevated High Sensitivity C-Reactive ProteinThe PIOSTAT Study
    Journal of the American College of Cardiology, vol. 49, no. 3, pp. 290–297, 2007
  8. Effect of simvastatin and/or pioglitazone on insulin resistance, insulin secretion, adiponectin, and proinsulin levels in nondiabetic patients at cardiovascular risk—the PIOSTAT Study
    Metabolism, vol. 56, no. 4, pp. 491–496, 2007
  9. Peripheral Leptin Levels in Narcoleptic Patients
    Diabetes Technology & Therapeutics, vol. 9, no. 4, pp. 348–353, 2007
  10. Dose escalating safety study of CNS 5161 HCl, a new neuronal glutamate receptor antagonist (NMDA) for the treatment of neuropathic pain
    British Journal of Clinical Pharmacology, vol. 64, no. 1, pp. 75–82, 2007
  11. Anticancer drugs induce mdr1 gene expression in recurrent ovarian cancer
    Anti-Cancer Drugs, vol. 17, no. 9, pp. 1041–1044, 2006
  12. Evaluation of CGMSR During Rapid Blood Glucose Changes in Patients with Type 1 Diabetes
    Diabetes Technology Therapeutics, vol. 8, no. 2, pp. 146–155, 2006
  13. High-Sensitivity C-Reactive Protein as Cardiovascular Risk Marker in Patients with Diabetes Mellitus
    Diabetes Technology Therapeutics, vol. 8, no. 1, pp. 28–36, 2006
  14. The Switch from Sulfonylurea to Preprandial Short- Acting Insulin Analog Substitution Has an Immediate and Comprehensive -Cell Protective Effect in Patients with Type 2 Diabetes Mellitus
    Diabetes Technology Therapeutics, vol. 8, no. 3, pp. 375–384, 2006
  15. Response to Jean-Luc Cracowski, Gregg R. McCord, Christopher T. Minson
    Journal of Diabetes and its Complications, vol. 20, no. 2, pp. 134–135, 2006
  16. Impact of rosiglitazone on beta-cell function, insulin resistance, and adiponectin concentrations: results from a double-blind oral combination study with glimepiride
    Metabolism, vol. 55, no. 1, pp. 20–25, 2006
  17. Pioglitazone: an antidiabetic drug with cardiovascular therapeutic effects
    Expert Review of Cardiovascular Therapy, vol. 4, no. 4, pp. 445–459, 2006
  18. Performance of the continuous glucose monitoring system (CGMS) during development of ketosis in patients on insulin pump therapy
    Diabetic Medicine, vol. 23, no. 10, pp. 1124–1129, 2006
  19. Association of high-sensitive C-reactive protein with advanced stage ?-cell dysfunction and insulin resistance in patients with type 2 diabetes mellitus
    Clinical Chemistry and Laboratory Medicine, vol. 44, no. 5, pp. 556–560, 2006
  20. Pioglitazone: an antidiabetic drug with the potency to reduce cardiovascular mortality
    Expert Opinion on Pharmacotherapy, vol. 7, no. 4, pp. 463–476, 2006
  21. Pioglitazone Decreases Carotid Intima-Media Thickness Independently of Glycemic Control in Patients With Type 2 Diabetes Mellitus: Results From a Controlled Randomized Study
    Circulation, vol. 111, no. 19, pp. 2525–2531, 2005
  22. Pulmonary insulin delivery by means of the Technosphere drug carrier mechanism
    Expert Opinion on Drug Delivery, vol. 2, no. 6, pp. 1097–1106, 2005
  23. Impact of insulin on microvascular blood flow and endothelial cell function in the postprandial state in patients with Type 1 diabetes
    Journal of Diabetes and its Complications, vol. 19, no. 3, pp. 128–132, 2005
  24. Improvement of Cardiovascular Risk Markers by Pioglitazone Is Independent From Glycemic ControlResults From the Pioneer Study
    Journal of the American College of Cardiology, vol. 45, no. 12, pp. 1925–1931, 2005
  25. Evaluation of the insulin application system Autopen 24®
    Practical Diabetes International, vol. 22, no. 9, pp. 364–366a, 2005
  26. IRIS II Study: Intact Proinsulin Is Confirmed as a Highly Specific Indicator for Insulin Resistance in a Large Cross-Sectional Study Design
    Diabetes Technology Therapeutics, vol. 7, no. 3, pp. 478–486, 2005
  27. Pioneer Study: PPAR? Activation Results in Overall Improvement of Clinical and Metabolic Markers Associated with Insulin Resistance Independent of Long-term Glucose Control
    Hormone and Metabolic Research, vol. 37, no. 8, pp. 510–515, 2005
  28. Evaluation of SET-A New Device for the Measurement of Pain Perception in Comparison to Standard Measures of Diabetic Neuropathy
    Diabetes Technology Therapeutics, vol. 6, no. 5, pp. 601–606, 2004
  29. IRIS II study: the IRIS II score-assessment of a new clinical algorithm for the classification of insulin resistance in patients with Type 2 diabetes
    Diabetic Medicine, vol. 21, no. 10, pp. 1149–1153, 2004
  30. Fasting Intact Proinsulin Is a Highly Specific Predictor of Insulin Resistance in Type 2 Diabetes
    Diabetes Care, vol. 27, no. 3, pp. 682–687, 2004
  31. Clinical and Laboratory Evaluation of Specific Chemiluminescence Assays for Intact and Total Proinsulin
    Clinical Chemistry and Laboratory Medicine, vol. 41, no. 9, pp. 1234–1238, 2003
  32. Pilot Study with Technosphere/PTH(1 - 34) - A New Approach for Effective Pulmonary Delivery of Parathyroid Hormone (1 - 34)
    Hormone and Metabolic Research, vol. 35, no. 5, pp. 319–323, 2003
  33. Stimulation of endothelial nitric oxide synthase by proinsulin C-peptide
    Nitric Oxide, vol. 9, no. 2, pp. 95–102, 2003
  34. Technosphere/InsulinA New Approach for Effective Delivery of Human Insulin Via the Pulmonary Route
    Diabetes Technology Therapeutics, vol. 4, no. 5, pp. 589–594, 2002
  35. TechnosphereTM/Insulin - proof of concept study with a new insulin formulation for pulmonary delivery
    Experimental and Clinical Endocrinology & Diabetes, vol. 110, no. 1, pp. 17–21, 2002
  36. Response to Jungheim and Koschinsky
    Diabetes Care, vol. 25, no. 3, pp. 638–639, 2002
  37. Impact of Diabetic Nephropathy on Pharmacodynamic and Pharmacokinetic Properties of Insulin in Type 1 Diabetic Patients
    Diabetes Care, vol. 24, no. 5, pp. 886–890, 2001
  38. Alternative Routes of Administration as an Approach to Improve Insulin Therapy: Update on Dermal, Oral, Nasal and Pulmonary Insulin Delivery
    Current Pharmaceutical Design, vol. 7, no. 14, pp. 1327–1351, 2001
  39. The influence of isolated small nerve fibre dysfunction on microvascular control in patients with diabetes mellitus
    Diabetic Medicine, vol. 18, no. 6, pp. 489–494, 2001
  40. Serum levels of substance P are decreased in patients with type 1 diabetes
    Experimental and Clinical Endocrinology & Diabetes, vol. 108, no. 3, pp. 164–167, 2000
  41. Effects of proinsulin C-peptide on nitric oxide, microvascular blood flow and erythrocyte Na+,K+-ATPase activity in diabetes mellitus type I
    Clinical Science, vol. 98, no. 3, p. 283, 2000
  42. Improved Diagnostic Methods in the Follow-Up of Medullary Thyroid Carcinoma by Highly Specific Calcitonin Measurements
    Journal of Clinical Endocrinology & Metabolism, vol. 85, no. 5, pp. 1890–1894, 2000
  43. Use of insulin lispro in continuous subcutaneous insulin infusion treatment. Results of a multicenter trial. German Humalog-CSII Study Group
    Diabetes Care, vol. 22, no. 5, pp. 784–788, 1999
  44. Pharmacokinetics and pharmacodynamics of insulin Lispro compared with regular insulin in haemodialysis patients with diabetes mellitus
    Nephrology Dialysis Transplantation, vol. 14, no. 90004, pp. 5–6, 1999
  45. Serum leptin is associated with serum uric acid concentrations in humans
    Metabolism, vol. 48, no. 6, pp. 677–680, 1999
  46. Elevated serum leptin concentrations in type 2 diabetic patients with microalbuminuria and macroalbuminuria
    Metabolism, vol. 48, no. 10, pp. 1290–1293, 1999
  47. The physiological impact of proinsulin C-peptide
    Pathophysiology, vol. 5, no. 4, pp. 257–262, 1999
  48. The effect of human proinsulin C-peptide on erythrocyte deformability in patients with Type I diabetes mellitus
    Diabetologia, vol. 42, no. 4, pp. 465–471, 1999
  49. Is there an ectopic secretion of monomeric calcitonin in the human being?
    Langenbeck's Archives of Surgery, vol. 383, no. 6, pp. 456–459, 1998
  50. Influence of sex differences in subcutaneous fat mass on serum leptin concentrations
    Diabetes Care, vol. 21, no. 7, pp. 1204–1205, 1998
  51. Comparison of the microvascular response to transcutaneous electrical nerve stimulation and postocclusive ischemia in the diabetic foot
    Journal of Diabetes and its Complications, vol. 11, no. 5, pp. 291–297, 1997
  52. Severe insulin resistance treated with insulin lispro
    The Lancet, vol. 349, no. 9046, pp. 211–211, 1997
  53. Severe insulin resistance treated with insulin lispro
    The Lancet, vol. 348, no. 9036, pp. 1248–1248, 1996
  54. Decreased sympatho-adrenal activity in diabetic patients with autonomic dysfunction following mental stress
    Journal of the Autonomic Nervous System, vol. 61, no. 1, pp. 31–36, 1996
  55. Autoantibodies to the islet antigen ICA 69 occur in IDDM and in rheumatoid arthritis
    Diabetologia, vol. 38, no. 3, pp. 351–355, 1995